Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Rare Disease Genome Editing Industry In 2025?
The market for rare disease genome editing has experienced rapid expansion in recent years. It is forecast to increase from $1.09 billion in 2024 to $1.29 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.9%. The market’s growth during the historical period was driven by increasing government funding for genetic research, a rising awareness of rare disease diagnosis, enhanced collaboration among biotech companies, and a surge in investment in personalized medicine.
The rare disease genome editing market size is projected to experience substantial growth in the coming years. Its value is expected to reach $2.46 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 17.6%. This expansion throughout the forecast period can be attributed to the increasing incorporation of AI in genome editing, a rising demand for targeted therapies, ongoing advancements in gene delivery systems, the growing prevalence of multi-gene disorders, and an increased emphasis on pediatric rare diseases. Noteworthy trends for the forecast period include enhancements in multi-gene editing techniques, the integration of AI-driven genomic analysis, personalized gene therapies facilitated by technology, developments in in vivo gene delivery systems, and progress in high-throughput genome screening.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Rare Disease Genome Editing Industry?
The expanding emphasis on precision medicine is projected to drive the growth of the rare disease genome editing market in the coming years. Precision medicine involves customizing prevention, diagnosis, and treatment based on an individual’s unique genetic composition, environmental factors, and lifestyle. This tailored healthcare strategy leverages a patient’s genetics, surroundings, and habits to deliver more precise and efficacious treatments. The heightened attention to precision medicine stems from breakthroughs in genomic sequencing and the identification of biomarkers, which facilitate accurate detection and targeted interventions. The rare disease genome editing market aids precision medicine by allowing for the specific correction of genetic mutations, thereby making therapies more individualized and effective. It enhances healthcare by tackling the fundamental cause of rare conditions, leading to better patient outcomes and lessening dependence on managing symptoms. For instance, in March 2024, Novotech, an Australia-based biotechnology company, in 2023, 43% of the 217 FDA-approved oncology therapies were precision oncology treatments, with 78 incorporating DNA or NGS-detectable biomarkers. Consequently, the rising focus on precision medicine is propelling the growth of the rare disease genome editing market.
How Is The Rare Disease Genome Editing Market Classified Into Different Segments?
The rare disease genome editing market covered in this report is segmented as
1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies
2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders
3) By Application: Therapeutics, Research
4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals
Subsegments:
1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing
2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases
3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)
4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases
Which Ongoing Trends Are Expected To Shape The Rare Disease Genome Editing Market Outlook?
Leading companies within the rare disease genome editing market are concentrating on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, with the goal of enhancing treatment precision, improving therapeutic outcomes, and addressing genetic diseases previously deemed incurable. These CRISPR-based gene editing systems are innovative technologies designed to enable precise modifications to the genome, allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. As an example, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and obtained conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). This therapy is indicated for patients aged 12 and older with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises or with transfusion-dependent beta thalassemia (TDT). Casgevy operates by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, a process that reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.
Who Are The Prominent Global Companies Shaping The Rare Disease Genome Editing Market?
Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., and MeiraGTx Holdings plc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report
How Do Regional Market Performances Compare Within The Rare Disease Genome Editing Industry?
North America was the largest region in the rare disease genome editing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare disease genome editing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Rare Disease Genome Editing Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28313&type=smp
Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2025, By The Business Research Company
Genome Editing Or Genome Engineering Global Market Report 2025
Crispr Gene Editing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report
Gene Editing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model